Filing Flows › Sight Sciences (SGHT) › Q3 2026 › vs Q2 2026
Sight Sciences (SGHT) Q3 2026 vs Q2 2026 (quarter over quarter)
Sight Sciences's revenue rose $1.5M (+7%) from $23.4M in Q2 2026 to $24.9M in Q3 2026. The biggest changes: Dry Eye +$1.2M (+45%); Surgical Glaucoma +$333K (+2%).
Sight Sciences, Q3 2026: revenue $24.9M (+25% year over year), operating margin -24.6%, net loss $6.8M, operating cash flow −$2.4M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Surgical Glaucoma | $21.0M | $20.7M | $333K | +2% |
| Dry Eye | $3.9M | $2.7M | $1.2M | +45% |
| Revenue | $24.9M | $23.4M | $1.5M | +7% |
| Net loss | $6.8M | $4.4M | $2.4M | +53% |
| Costs & expenses | $31.7M | $27.8M | $3.9M | +14% |
| Operating costs | $31.1M | $27.3M | $3.8M | +14% |
| Interest & other, net | $671K | $530K | $141K | +27% |
| Income tax | $11K | $28K | −$17K | -61% |
| Cost of revenue | $3.5M | $2.0M | $1.5M | +74% |
| Research & development | $2.7M | $2.5M | $194K | +8% |
| SG&A | $24.8M | $22.8M | $2.1M | +9% |
| Operating cash sources | $6.8M | $4.4M | $2.4M | +53% |
| Depreciation & amortization | $110K | $94K | $16K | +17% |
| Share-based compensation | $2.9M | $3.0M | −$29K | -1% |
| Working capital & other | $1.4M | −$4.3M | $5.6M | — |
| Cash used in operations | $2.4M | $5.7M | −$3.3M | -58% |
| Net loss absorbed | $6.8M | $4.4M | $2.4M | +53% |
Questions
How much did Sight Sciences's revenue grow quarter over quarter in Q3 2026?
Sight Sciences's revenue rose $1.5M (+7%) from $23.4M in Q2 2026 to $24.9M in Q3 2026.
What drove Sight Sciences's revenue change in Q3 2026?
Dry Eye +$1.2M (+45%); Surgical Glaucoma +$333K (+2%).